Abstract
The bioavailability of two different s.c. doses of Desmin (a new low molecular weight dermatan sulfate) was evaluated in 12 healthy volunteers (6 men, 6 women aged 22–45 years) who were injected, on 3 separate days and with a wash-out period of at least 21 days between each administration, with 200 and 300 mg of Desmin by the s.c. route and 200 mg by the i.v. route. Immediately before injection and at various times thereafter (after 15 min and 30 min for i.v. only and after 1, 2, 3, 4, 6, 8, 12, and 24 h for both s.c. and i.v. dosing), blood samples were drawn to investigate bioavailability by measuring several coagulation parameters: activated partial thromboplastin time, thrombin time, inhibition of factor Xa, Heptest, and heparin cofactor II. Furthermore the local tolerance of the s.c. and i.v. injections were investigated. The s.c. administration of the two Desmin doses had a negligible effect on the activated partial thromboplastin time and a very small effect on the thrombin time, measured with human thrombin; in contrast, Heptest, heparin cofactor II, and anti-Xa activities increased, with a good drug bioavailability (more than 100%). The plasma effects of Desmin were dose dependent only when measured by Heptest, which also gave a greater response after the s.c. administrations. There were no symptoms of intolerance or pain at the injection site after single i.v. and s.c. Desmin administrations.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258:6713.
Mascellani G, Bianchini P. European Patent 1990, no. 0221977. USA Patent no. 4973580.
Tamagnone G, Barbanti M. Desmin-370. Drugs Fut 1994; 19: 638.
Barbanti M, Calanni F, Babbini M, Bergonzini G, Parma B, Marchi E. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res 1993; 71:417.
Bergonzini GL, Bianchini P, Hoppensteadt Parma B, Osima B, Walenga JM, Fareed J. Pharmacokinetics of native and low molecular weight dermatan: preliminary results in rats and primates. Semin Thromb Hemost 1991 ; 17 (Suppl 2):235.
Barbanti M, Caianni F, Milani M, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis-evidence for an anticoagulant-independent mechanism. Thromb Haemost 1993; 69:147.
Barbanti M. Calanni F, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in experimental venous thrombosis in rat: comparison with t-PA and u-PA (abstract). Thromb Haemost 1993; 69: 860.
Barbanti M, Calanni F, Marchi E, Semeraro N, Colucci M. Desmin 370, a low molecular weight dermatan sulphate reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod. Thromb Haemost 1995; 73:287.
Dettori AG, Galli G, Manotti C, Palazzini E. Pharmacological activity of a low molecular weight dermatan sulphate (Desmin) in healthy volunteers. Semin Thromb Hemost 1994: 20:259.
Legnani C, Palareti G, Biagi R, Ludovici S, Maggiore L, Milani M, Coccheri S. Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Eur J Clin Pharmacol 1994; 47:247.
Dettori AG, Milani MR, Manotti C, Zamboni V, Palazzini E, Barbanti M. Pharmacology of Desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Thromb Res 1995; 79:249.
Cucinotta D, Manopulo R, Galati M, Zamboni V, Palazzini E, Barbanti M, Milani MR. Pharmacodynamics of a new low-molecular-weight dermatan sulfate after single subcutaneous injection in elderly patients with chronic venous disorders: a phase I trial. Curr Ther Res 1994; 55:1492.
Traini AM, Cervi V, Melandri G, Palazzini E, Zamboni V, Semprini F, Candiotti N, Branzi A. Pharmacodynamic characteristics of a low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction. J Int Med Res 1994; 22:323.
Huskisson EC. Measurement of pain. Lancet 1974; II:1127.
Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990; 13:227.
Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990; 5:585.
Tripodi A, Moia M, Bottasso B, Tenconi PM, Gianese F, Mannucci PM. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 1991; 62:663.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miglioli, M., Pironi, L., Ruggeri, E. et al. Bioavailability of Desmin, a low molecular weight dermatan sulfate, affer subcutaneous administration to healthy volunteers. Int J Clin Lab Res 27, 195–198 (1997). https://doi.org/10.1007/BF02912457
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02912457